[go: up one dir, main page]

MA32224B1 - Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales - Google Patents

Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Info

Publication number
MA32224B1
MA32224B1 MA33241A MA33241A MA32224B1 MA 32224 B1 MA32224 B1 MA 32224B1 MA 33241 A MA33241 A MA 33241A MA 33241 A MA33241 A MA 33241A MA 32224 B1 MA32224 B1 MA 32224B1
Authority
MA
Morocco
Prior art keywords
treatment
carbonyl
pyrazolyl
diseases
retroviral diseases
Prior art date
Application number
MA33241A
Other languages
Arabic (ar)
English (en)
Inventor
Kai Thede
Susanne Greschat
Steffen Wildum
Daniela Paulsen
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA32224B1 publication Critical patent/MA32224B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles (pyrazolyl-carbonyl)imidazolidinones (i) substituées, leur procédé de fabrication, leur utilisation pour le traitement et/ou la prophylaxie de maladies, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de maladies rétrovirales, chez l'homme et/ou l'animal.
MA33241A 2008-03-17 2010-10-11 Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales MA32224B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008015033A DE102008015033A1 (de) 2008-03-17 2008-03-17 Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
PCT/EP2009/001714 WO2009115213A1 (fr) 2008-03-17 2009-03-10 Dérivés de (pyrazolyl-carbonyl)imidazolidinone pour le traitement de maladies rétrovirales

Publications (1)

Publication Number Publication Date
MA32224B1 true MA32224B1 (fr) 2011-04-01

Family

ID=40565083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33241A MA32224B1 (fr) 2008-03-17 2010-10-11 Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Country Status (22)

Country Link
US (1) US8399682B2 (fr)
EP (1) EP2254885B1 (fr)
JP (1) JP5576853B2 (fr)
KR (1) KR20100124337A (fr)
CN (1) CN101977908B (fr)
AP (1) AP2774A (fr)
AR (1) AR070919A1 (fr)
AU (1) AU2009226656A1 (fr)
CA (1) CA2718685C (fr)
CL (1) CL2009000636A1 (fr)
DE (1) DE102008015033A1 (fr)
IL (1) IL207649A0 (fr)
MA (1) MA32224B1 (fr)
MX (1) MX2010010230A (fr)
NZ (1) NZ588141A (fr)
PE (1) PE20091718A1 (fr)
RU (1) RU2010141578A (fr)
TW (1) TW200951125A (fr)
UA (1) UA102390C2 (fr)
UY (1) UY31717A1 (fr)
WO (1) WO2009115213A1 (fr)
ZA (1) ZA201007361B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008015032A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
EP2295038B1 (fr) * 2009-09-11 2013-05-29 AiCuris GmbH & Co. KG Dispersion solide comprenant un agent anti-VIH
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US3806506A (en) * 1971-08-05 1974-04-23 Uniroyal Inc Furan derivatives,compositions thereof and methods for using same
DE3119796A1 (de) 1981-05-19 1982-12-23 Hoechst Ag, 6000 Frankfurt Substituierte tryptaminderivate von thienyloxpropanolaminen, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen sowie ihre verwendung
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH084281B2 (ja) * 1992-09-30 1996-01-17 橋本コーポレイション株式会社 オンフック後相手の声を拡声する電話装置
FR2728571B1 (fr) * 1994-12-22 1997-01-31 Adir Nouveaux ethers d'oximes tricycliques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5696151A (en) 1995-11-30 1997-12-09 Uniroyal Chemical Company, Inc. Compounds useful for the inhibition of the replication of HIV-1 and HIV-1 mutants
US6143780A (en) * 1999-09-17 2000-11-07 Uniroyal Chemical Company, Inc. N-arylmethylthioanilide compounds useful for the inhibition of the replication of HIV
EP1299381B1 (fr) 2000-06-28 2008-05-07 AstraZeneca AB Derives de la quinazoline substitues et leur utilisation comme inhibiteurs
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
JP2005501841A (ja) 2001-08-01 2005-01-20 バセル ポリオレフィン ジーエムビーエイチ 複素環式ペンタレン誘導体の製造方法
CA2465207C (fr) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides et -sulfonamides
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US7166619B2 (en) * 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
GB0221477D0 (en) * 2002-09-16 2002-10-23 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
KR20050083761A (ko) 2002-12-02 2005-08-26 후지사와 야꾸힝 고교 가부시키가이샤 Cox-i저해제로서 유용한 피라졸 유도체
PL377848A1 (pl) * 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
MXPA05006861A (es) 2003-02-27 2005-12-12 Neurosearch As Derivados arildiazabiciclicos novedosos.
FR2856683A1 (fr) 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
PL2298743T3 (pl) * 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
US7220772B2 (en) * 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
FR2860792B1 (fr) 2003-10-10 2006-02-24 Sanofi Synthelabo Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
US20090149463A1 (en) 2004-02-20 2009-06-11 Leifeng Cheng Therapeutic agents
JPWO2006004027A1 (ja) * 2004-07-01 2008-04-24 第一製薬株式会社 ピラゾール誘導体
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
US7705025B2 (en) 2004-08-23 2010-04-27 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP1828169A2 (fr) 2004-12-07 2007-09-05 Locus Pharmaceuticals, Inc. Inhibiteurs urée de map kinases
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
KR20070090922A (ko) 2004-12-15 2007-09-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
JP2008533042A (ja) 2005-03-10 2008-08-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン 過剰増殖性疾患の処置のためのピリミジン誘導体
EP1910307A1 (fr) 2005-06-27 2008-04-16 Exelixis, Inc. Modulateurs des lxr a base de pyrazoles
EP1743637A1 (fr) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique
ES2326723B1 (es) 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazol sustituidos y combinaciones de los mismos para el tratamiento del sindrome metabolico.
GB0516661D0 (en) 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
AU2007306382A1 (en) 2006-10-12 2008-04-17 Janssen Pharmaceutica Nv Substituted pyrazinone derivatives for use as a medicine
EP2099770B1 (fr) 2006-12-21 2015-06-10 Sloan-Kettering Institute for Cancer Research Pyridazinones et composés furanniques
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung

Also Published As

Publication number Publication date
AP2774A (en) 2013-09-30
AP2010005422A0 (en) 2010-10-31
AR070919A1 (es) 2010-05-12
PE20091718A1 (es) 2009-12-11
CA2718685A1 (fr) 2009-09-24
JP2011514366A (ja) 2011-05-06
CN101977908B (zh) 2014-04-23
AU2009226656A1 (en) 2009-09-24
KR20100124337A (ko) 2010-11-26
JP5576853B2 (ja) 2014-08-20
NZ588141A (en) 2012-05-25
UY31717A1 (es) 2009-08-31
ZA201007361B (en) 2011-12-28
UA102390C2 (ru) 2013-07-10
EP2254885B1 (fr) 2013-12-04
US20110124618A1 (en) 2011-05-26
DE102008015033A1 (de) 2009-09-24
CA2718685C (fr) 2016-11-29
US8399682B2 (en) 2013-03-19
CN101977908A (zh) 2011-02-16
TW200951125A (en) 2009-12-16
MX2010010230A (es) 2010-11-09
CL2009000636A1 (es) 2010-05-07
WO2009115213A1 (fr) 2009-09-24
IL207649A0 (en) 2010-12-30
RU2010141578A (ru) 2012-04-27
EP2254885A1 (fr) 2010-12-01

Similar Documents

Publication Publication Date Title
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA201170227A1 (ru) Имидазолкарбоксамиды
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201790267A1 (ru) Новые модуляторы киназ
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201100032A1 (ru) Соединения пиридина
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201170349A1 (ru) Модуляторы mif
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида